In summary, our results suggest that FGL1 may be an important regulator of EGFR-TKI resistance in NSCLC and targeting FGL1 may be a promising approach to solving the problem of EGFR-TKI acquired resistance. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.